The Food and Drug Administration has accepted Insmed's application seeking full approval of ARIKAYCE, an inhaled antibiotic for Mycobacterium avium complex (MAC) lung disease, and granted it priority review, the company announced Sept. 21. The agency set a target action date of Jan. 28, 2027.
This is a regulatory milestone, not a new approval. But it matters for patients who cannot get the drug today. ARIKAYCE's current label covers only adults with limited treatment options whose infections did not clear after at least six months of standard multidrug therapy. The new application is based on a trial in people with a new MAC infection who had not yet received antibiotics, and it could move the drug earlier in treatment if the FDA agrees.
For older adults with chronic cough, fatigue, and repeated lung infections, and for the families who care for them, the practical questions are whether they might become eligible sooner and what the drug's side effects mean for daily life.
A Narrow Label Built on Accelerated Approval
ARIKAYCE received accelerated approval in 2018 and was the first product cleared under the FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs, according to Insmed's announcement. That approval was based on sputum culture conversion, meaning lab tests stopped detecting the bacteria. The current label states that clinical benefit has not yet been established.
Accelerated approval requires a confirmatory study, and Insmed says its Phase 3b ENCORE trial was designed to meet that requirement. The FDA grants priority review to applications for medicines that, if approved, would provide a significant improvement in safety or effectiveness in treating a serious condition.
Dr. Martina Flammer, Insmed's chief medical officer, described MAC lung disease as progressive and said "The longer the infection persists, the greater the damage to lung tissue and the harder it becomes to treat." She added that full approval could let the drug reach patients earlier, including those newly diagnosed or facing recurrent infections.
ENCORE Trial Results in Patients with New Infections
ENCORE enrolled 425 adults at 177 sites worldwide who had a new occurrence of MAC lung infection and had not received antibiotics. Most, 82.4%, were facing their first infection, while the rest had a second or third. Patients were randomly assigned to ARIKAYCE or a placebo, each added to azithromycin and ethambutol, for 12 months, followed by three months off treatment.
In topline results released in March, respiratory symptom scores improved by 17.77 points in the ARIKAYCE group versus 14.66 points with placebo, a statistically significant difference of 3.11 points. Durable culture conversion, meaning the infection stayed undetectable after treatment ended, reached 76.2% versus 47.6%. A fatigue measure did not improve significantly, Healio reported, and more patients stopped treatment in the ARIKAYCE group.
These are company-reported results from a company-funded trial. MedicalDaily did not find a full peer-reviewed publication of ENCORE, and the FDA will review the complete dataset before deciding. Insmed reported no new safety signals.
Side Effects and Who Is at Risk
ARIKAYCE carries a boxed warning for respiratory side effects. In the earlier trial behind its 2018 approval, bronchospasm occurred in 28.7% of patients using ARIKAYCE plus a background regimen versus 10.7% on the regimen alone. Coughing up blood occurred in 17.9% versus 12.5%, and hypersensitivity pneumonitis, an allergic lung reaction, in 3.1% versus none.
Hearing and balance problems, including tinnitus and dizziness, occurred in 17% versus 9.8%. Voice changes were the most common side effect, reported by 47% of users. The drug is inhaled once daily through a portable nebulizer.
MAC bacteria live in soil and water, and the infection does not generally spread from person to person. Those at higher risk include older adults, especially women, and people with bronchiectasis, COPD, or weakened immune systems. A CDC journal study of hospital data from 1998 to 2005 found that hospitalizations for this type of lung disease rose sharply with age, with significant yearly increases in Florida and among women in New York.
Warning signs include a cough lasting weeks, fatigue, fever, night sweats, unexplained weight loss, and shortness of breath. Coughing up blood, chest pain, or severe breathing trouble needs urgent care.
Costs, Access, and the January Decision
ARIKAYCE is a specialty drug, and coverage often requires prior authorization. Patients can ask their pulmonologist and insurer how the current label affects eligibility, and Insmed lists patient access resources on its website. Even if the label expands, insurers may set their own criteria.
No one should change a MAC treatment plan based on this news. By Jan. 28, 2027, the FDA could approve the expanded use, ask for more information, or decline. Insmed also plans to review the data with Japanese regulators in the fourth quarter of 2026.
A broader option may be coming for patients with new MAC infections, but it is not here yet. People with a persistent cough or repeated lung infections can ask whether testing for these bacteria makes sense, and those already diagnosed should keep working with a specialist on the regimen that fits them.
Key Questions Answered
Did the FDA approve ARIKAYCE for more patients? No. The FDA accepted Insmed's application and granted priority review. A decision is expected by Jan. 28, 2027.
Who can use ARIKAYCE now? Adults with limited treatment options whose MAC lung infection did not clear after at least six months of multidrug therapy.
What did the ENCORE trial show? Company-reported results showed better respiratory symptom scores and higher rates of lasting culture conversion when ARIKAYCE was added to standard therapy.
What are the main side effects? Voice changes, cough, bronchospasm, coughing up blood, and hearing or balance problems are among the reported effects.
Is MAC lung disease contagious? It generally does not spread between people. The bacteria come from soil and water.
Who is most at risk? Older adults, especially women, and people with bronchiectasis, COPD, or weakened immune systems.
